LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

Abstract

These findings support the use of the LABA/LAMA, QVA149 as an alternative treatment, over LABA/inhaled corticosteroid, in the management of moderate-to-severe COPD patients (GOLD B and GOLD D) with a history of ≤1 exacerbation in the previous year.